文献速递心力衰竭与心肌病

心力衰竭患者接受高剂量静脉袢利尿剂的耳毒性评估

Assessment of Ototoxicity in Patients With Heart Failure Receiving High-Dose IV Loop Diuretics.
PubMed 文献 · JAMA Cardiol · 2026-10-30

该研究通过三个队列评估袢利尿剂剂量与永久性和暂时性耳毒性的关联。两个小型心衰队列中,短期高剂量袢利尿剂暴露未与永久性耳毒性相关,仅在血药浓度峰值时出现短暂听力变化;回顾性队列中临床诊断耳毒性与高剂量无显著关联。

要点

  • 短期高剂量静脉袢利尿剂未增加永久性耳毒性风险。
  • 听力变化在血药浓度峰值时短暂出现,数小时内大多恢复。
  • 临床诊断耳毒性与袢利尿剂峰值剂量无显著关联。

核心结论

  • 在两个小型心衰队列中,短期高剂量袢利尿剂暴露未与永久性耳毒性相关,但排除了同时使用耳毒性药物者。

研究设计与样本

  • 队列1:50例稳定心衰门诊患者,随机接受不同剂量布美他尼(1.25-10 mg)并系列听力检测。
  • 队列2:40例急性心衰住院患者,接受系列静脉袢利尿剂至呋塞米500 mg,基线和出院前听力检测。
  • 队列3:回顾性多中心队列,22 656例心衰住院患者,用ICD-10编码定义临床诊断耳毒性。

主要发现

  • 队列1和2中未观察到临床诊断耳毒性。
  • 队列1听力变化数小时内大多恢复,98%的测量(400次给药中393耳)无听力变化。
  • 队列2听力变化与利尿剂剂量无关(每倍剂量OR 1.19;95%CI 0.71-1.98;P=0.52)。

临床怎么用

  • 短期高剂量静脉袢利尿剂用于心衰时,永久性耳毒性风险较低,但需注意血药浓度峰值时的短暂听力变化。
  • 避免同时使用其他耳毒性药物,因研究排除了此类患者。
  • 重复暴露和更广泛人群的耳毒性风险仍需进一步研究。

局限性

  • 队列1和2样本量小(分别为50和40例)。
  • 研究排除了同时使用耳毒性药物的患者。
  • 需进一步研究重复暴露和更广泛心衰人群的耳毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Concern for ototoxicity hinders loop diuretic (LD) dosing in heart failure (HF); given the mechanism by which LDs affect the ear, high-dose LDs should produce transient, not permanent, hearing changes. OBJECTIVE: To measure the association of LD dose with permanent and temporary ototoxicity. DESIGN, SETTING, AND PARTICIPANTS: Cohort 1 received a randomized sequence of LD doses (bumetanide, 1.25-10 mg) across study visits with serial audiometry assessments. Cohort 2 received serial LD up to furosemide 500-mg doses during a HF hospitalization with audiometry at baseline and prior to discharge. Cohort 3 retrospectively characterized clinically diagnosed ototoxicity in HF hospitalizations was defined using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Cohorts 1 and 2 were single center, while cohort 3 was multicenter. Cohort 1 studied outpatient participants with stable HF, while cohort 2 (n = 40) and cohort 3 studied hospitalized patients with acute HF. EXPOSURE: Intravenous LD. MAIN OUTCOMES AND MEASURES: The primary outcomes were clinically diagnosed ototoxicity and hearing changes via audiometry. RESULTS: Cohort 1 contained 50 participants, cohort 2 contained 40 participants, and cohort 3 contained 22 656 participants. In cohort 1, mean (SD) participant age was 63.2 (10.4) years, and 21 of 50 participants (42%) were women. In cohorts 1 and 2, clinically diagnosed ototoxicity was not observed. In cohort 1, at peak diuretic concentration, worsening hearing shifts were infrequent (24 ears of 400 doses [6%]) but were more common with higher doses (odds ratio [OR], 1.99; 95% CI, 1.21-3.28 per doubling dose; P = .007). Within hours, hearing shifts largely resolved and were absent in 98% of measurements (393 ears of 400 doses). No significant association between LD dose and hearing shifts was present at any time aside from peak LD concentration. In cohort 2, hearing shifts were not different across groups divided by the median daily LD dose and were not associated with LD dose (OR, 1.19; 95% CI, 0.71-1.98 per doubling dose; P = .52). In cohort 3, 608 HF hospitalizations (2.7%) had clinically diagnosed ototoxicity. In multivariable analyses, peak dose of 160 mg furosemide equivalents or greater (OR, 0.83; 95% CI, 0.52-1.31; P = .43) and 400 mg furosemide equivalents or greater (OR, 1.28; 95% CI, 0.71-2.31; P = .41) were not associated with greater clinically diagnosed ototoxicity risk relative to less than 160 mg. CONCLUSIONS AND RELEVANCE: In this analysis of 2 small HF cohorts, short-term exposure to high-dose LD was not associated with permanent ototoxicity, although concomitant ototoxin use was excluded. Future studies are needed to understand the risk of ototoxicity with repeated LD exposure and in broader HF populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT04481919 and NCT05323487.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Cox, Rao, Ivey-Miranda, et al. Assessment of Ototoxicity in Patients With Heart Failure Receiving High-Dose IV Loop Diuretics. JAMA Cardiol. 2026. PMID: 42961411. doi:10.1001/jamacardio.2026.4913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。